Karen Wernli, PhD, is a cancer epidemiologist and health services researcher whose work focuses on incorporating patient-centered outcomes to improve cancer care along the cancer care continuum, from prevention to survivorship. Her works spans several types of cancer, including lung, breast, and colorectal, and also explores the impact of cancer in special populations, such as adolescents and young adults. Her research strives to answer critical questions at the confluence of patients’ needs and clinical priorities. Overall, her research has resulted in more than $15.5 million in external research funding, over 115 peer-reviewed publications, and more than 70 presentations at national conferences, symposia, and other public venues.
Dr. Wernli is a leader in multilevel intervention studies to improve lung cancer screening. She is currently conducting a pragmatic clinical trial funded by the National Cancer Institute (NCI) to test 2 multilevel interventions to improve adherence to annual lung cancer screening at Kaiser Permanente Washington (R01CA262015). Study interventions were developed using a mixed-methods approach, including patient and stakeholder engagement and human-centered design methods, to determine gaps for interventions, relevant features of interventions, and design concepts. Further, Dr. Wernli is also leading a pilot grant from the Alliance for Clinical Trials in Oncology to develop interventions to improve timely follow-up after a positive lung cancer screening scan. The purpose of the pilot grant is to develop a larger project within the NCI Community Oncology Research Program (NCORP).
Dr. Wernli is a leader in the use of breast imaging in women with prior breast cancer, including in the use of breast magnetic resonance imaging (MRI). Dr. Wernli recently completed a Patient-Centered Outcomes Research Institute (PCORI) project that compared breast MRI to mammography for women already treated for breast cancer. Called Surveillance Imaging Modalities for Breast Cancer Assessment (SIMBA), the study used data from the Breast Cancer Surveillance Consortium (BCSC) and engaged patients and stakeholders to determine the best information for patient and physician decision-making. Dr. Wernli’s team translated that information into a new decision aid for breast cancer survivors. PCORI has recognized this work nationally and pointed to SIMBA as a model for effective patient engagement.
Dr. Wernli’s other breast cancer projects include collaborating with Dr. Natasha Stout from Harvard University on an NCI-funded study to examine trends and outcomes related to the mandatory notification of breast density that has been enacted in many states. She also led research to determine temporal trends in the use of breast MRI over 10 years, based on indication for the scans. The analysis relied on national claims-based data across all 50 states.
Dr. Wernli is leading patient-centered research in adolescent and young adult (AYA) populations. She is currently a project co-lead with Kaiser Permanente Southern California researcher Dr. Erin Hahn and Veterans Affairs researcher Dr. Neetu Chawla in an NCI-funded program project to evaluate health service utilization in early survivorship for AYA populations. The research is intended to identify multilevel gaps in health care utilization in AYA early-cancer survivors for forthcoming interventions. Previously, Dr. Wernli launched the Clare Project with KPWHRI researchers, including Dr. Marlaine Figueroa Gray, to understand patient, caregiver, and provider perspectives regarding medical decision-making for patients with advanced cancer. Using novel methods, all perspectives were garnered through social media recruitment. With NCI-funding, she has evaluated temporal trends and regional variation in end-of-life care in AYA cancer populations using national claims-based data.
Finally, Dr. Wernli is expanding her research expertise in clinical research studies. She is currently the Cancer Care Delivery Research lead at Kaiser Permanente Washington. She is also principal investigator for KPWA of a multisite study of flu and COVID vaccine effectiveness funded by the Centers for Disease Control and Prevention.
Dr. Wernli is a member of the American Society for Preventive Oncology, the Society for Epidemiologic Research, the American Society for Clinical Oncology, and the American Association for Cancer Research. She is a standing reviewer for the American Cancer Society, and routinely reviews grants for the National Institutes of Health. She is also an affiliate associate professor of population and epidemiology at the University of Washington.
Breast, lung, colorectal, ovarian, skin, and endometrial cancer; screening and surveillance; survivorship; patient-centered care; biostatistics; low-dose CT (LDCT); mammography; surveillance imaging; breast magnetic resonance imaging (MRI); systematic reviews; multilevel intervention studies; pragmatic clinical trials
Comparative effectiveness research, health outcomes research, patient-centered outcomes, health care quality, implementation science
Cancer screening and surveillance
Patient engagement, stakeholder engagement, qualitative research methods, mixed-methods, human-centered design
Thompson MJ, Suchsland MZ, Hardy V, Lavallee D, Jarvik J, Walter F, Trikalinos T, Findlay S, Chou R, Green B, Wernli KJ, Lord S, Devine B, Bossuyt P. Patient-centred outcomes of imaging tests: recommendations for patients, clinicians and researchers. BMJ Qual Saf. 2021 Oct 6;bmjqs-2021-013311. doi: 10.1136/bmjqs-2021-013311. Online ahead of print. PubMed
Bowles EJA, O'Neill SC, Li T, Knerr S, Mandelblatt JS, Schwartz MD, Jayasekera J, Leppig K, Ehrlich K, Farrell D, Gao H, Graham AL, Luta G, Wernli KJ. Effect of a randomized trial of a web-based intervention on patient-provider communication about breast density. J Womens Health (Larchmt). 2021 Sep 28. doi: 10.1089/jwh.2021.0053 [Epub ahead of print] PubMed
Kerlavage AR, Kirchhoff AC, Guidry Auvil JM, Sharpless NE, Davis KL, Reilly K, Reaman G, Penberthy L, Deapen D, Hwang A, Durbin E, Gallotto S, Aplenc R, Volchenboum S, Heath A, Aronow B, Zhang J, Vaske O, Alonzo T, Nathan P, Poynter J, Armstrong G, Hahn E, Wernli KJ, Greene C, DiGiovanna J, Resnick A, Shalley E, Nadaf S, Kibbe W. Cancer informatics for cancer centers: scientific drivers for informatics, data science, and care in pediatric, adolescent, and young adult cancer. JCO Clin Cancer Inform. 2021 Aug;5:881-896. doi: 10.1200/CCI.21.00040. PubMed
Schifferdecker KE, Vaclavik D, Wernli KJ, Buist DSM, Kerlikowske K, Sprague, BL, Henderson LM, Johnson D, Budesky J, Jackson-Nefertiti G, Miglioretti DL, Tosteson ANA. Women’s considerations and experiences for breast cancer screening and surveillance during the COVID-19 pandemic in the United States: a focus group study. Prev Med. 2021 Oct;151:106542. doi: 10.1016/j.ypmed.2021.106542. Epub 2021 Jun 30. PubMed
Zhang D, Abraham L, Demb J, Miglioretti DL, Advani S, Sprague BL, Henderson LM, Onega T, Wernli KJ, Walter LC, Kerlikowske K, Schousboe JT, O'Meara ES, Braithwaite D. Function-related indicators and outcomes of screening mammography in older women: evidence from the Breast Cancer Surveillance Consortium cohort. Cancer Epidemiol Biomarkers Prev. 2021 Aug;30(8):1582-1590. doi: 10.1158/1055-9965.EPI-21-0152. Epub 2021 Jun 2. PubMed
Lee JM, Ichikawa LE, Wernli KJ, Bowles E, Specht JM, Kerlikowske K, Miglioretti DL, Lowry KP, Tosteson ANA, Stout NK, Houssami N, Onega T, Buist DSM. Digital mammography and breast tomosynthesis performance in women with a personal history of breast cancer, 2007-2016. Radiology. 2021 Aug;300(2):290-300. doi: 10.1148/radiol.2021204581. Epub 2021 May 18. PubMed
Miglioretti DL, Bissell MCS, Kerlikowske K, Buist DSM, Cummings SR, Henderson LM, Onega T, O'Meara ES, Rauscher GH, Sprague BL, Tosteson ANA, Wernli KJ, Lee JM, Lee CI. Assessment of a risk-based approach for triaging mammography examinations during periods of reduced capacity. JAMA Netw Open. 2021;4(3):e211974. doi: 10.1001/jamanetworkopen.2021.1974. PubMed
Wernli KJ, Bowles EA, Knerr S, Leppig KA, Ehrlich K, Gao H, Schwartz MD, O’Neill SC. Characteristics associated with participation in Engaged 2 - a web-based breast cancer risk communication and decision support trial. Perm J. 2020 Dec;24:1-4. doi: 10.7812/TPP/19.205. PubMed
Wernli KJ, Knerr S, Li T, Leppig K, Ehrlich K, Farrell D, Gao H, Bowles EA, Graham AL, Luta G, Jayasekera J, Mandelblatt JS, Schwartz MD, O’Neill SC. Effect of personalized breast cancer risk tool on chemoprevention and breast imaging: ENGAGED-2 trial. J Natl Cancer Inst. 2021 Jan 14;5(1):pkaa114. doi: 10.1093/jncics/pkaa114. eCollection 2021 Feb. PubMed
Wernli KJ, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK. Trends in screening breast magnetic resonance imaging use among US women, 2006 to 2016. Cancer. 2020 Sep 28. doi: 10.1002/cncr.33140. [Epub ahead of print]. PubMed
New research spotlights overdiagnosis, MRI before surgery, and a new way of predicting breast cancer risk
The VOICE study aims to improve the health and health care of people who had cancer as adolescents and young adults.
By partnering with patients, KPWHRI researchers developed 2 new interventions to boost lung cancer screening.
New study calculates risk-based approach to detect the most cancers with the fewest exams.
An epidemiologist identifies who is appropriately undergoing this imaging for breast cancer and who is not.
Now’s the time, Dr. Wernli says, to weigh in on lowering eligible age and pack-years smoked.